trial · primary record
Elismetrep
Migraine
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1500 |
| Primary completion | 2027-12 |
| Primary endpoint | Pain freedom at 2 hours post-dose |
| Registry ID | NCT07816367 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:43:44.996Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07816367
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Elismetrep · compound